论文部分内容阅读
2015年7月24日(FDA新闻发布)—美国FDA批准Technivie(ombitasvir、paritaprevir和利托那韦)与利巴韦林联合用于治疗基因型4丙型肝炎(HCV)感染无瘢痕和肝硬化的患者。美国丙型肝炎病毒感染者约为270万,其中病毒基因型4最为少见。Technivie是首个与利巴韦林联合在无需使用干扰素情况下用于治疗基因型4 HCV感染安全有效的药物。一项包括135例基因型4 HCV感染无肝硬化受试者的临床研究。该研究中91例受试者接受
July 24, 2015 (FDA Press Releases) - FDA Approves Technivie (ombitasvir, paritaprevir, and Ritonavir) in Combination with Ribavirin for the Treatment of Genital-4 Hepatitis C (HCV) Infection-Free Scar and Cirrhosis Of patients. In the United States, about 2.7 million people are infected with hepatitis C virus, of which the virus genotype 4 is the most rare. Technivie is the first drug to be effective with ribavirin for the treatment of genotype 4 HCV infection without interferon. A clinical study involving 135 genotype 4 HCV-infected subjects without cirrhosis. Ninety-one subjects in the study were accepted